Uji klinis HPV di Texas
6 studi untuk HPV mencari peserta di lokasi di Texas.
Kota di Texas
Teks studi resmi (Bahasa Inggris)
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
- University of Texas Medical Branch, Galveston
Menerima pesertaFase 4Sukarelawan sehat diterimaMenyebutkan pembayaran untuk peserta
Usia 27 hingga 45 · Wanita · Diperbarui 15 Sep 2026 · NCT05672927A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The University of Texas, MD Anderson Cancer Center, Houston
- UT Health Mays Cancer Center, San Antonio
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
- UT MD Anderson Cancer Center, Houston
Menerima pesertaSukarelawan sehat diterima
Usia 25 ke atas · Wanita · Diperbarui 31 Jul 2026 · NCT07281430Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
- The University of Texas Health Science Center at Houston, Houston
Menerima peserta
Usia 11 hingga 17 · Semua jenis kelamin · Diperbarui 4 Mei 2026 · NCT06598475Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
- The Harris Health System (L.B.J Hospital), Houston
- University of Texas, M.D. Anderson, Houston
Menerima pesertaFase 2
Usia 25 hingga 100 · Wanita · Diperbarui 2 Okt 2025 · NCT04098744HPV Vaccine, Imiquimod, and Metformin Combination Trial
- Baylor St. Luke's Medical Center- Dan L. Duncan Comprehensive Cancer Center, Houston
- Harris Health Smith Clinic, Houston
Menerima pesertaFase 2
Usia 18 hingga 64 · Wanita · Diperbarui 13 Nov 2024 · NCT06686043Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.